<p>根据 Nuveen LLC 最近向 SEC 提交的 13F 表格，该公司在第一季度收购了 Aerovate Therapeutics, Inc.（NASDAQ:AVTE - 免费报告）的新头寸。这家机构投资者收购了 40,047 股该公司的股票，价值约为 101,000 美元。截至最近报告期末，Nuveen LLC 持有 Aerovate Therapeutics 约 0.14% 的股份。</p>
<p>其他机构投资者和对冲基金也增加或减少了在该公司的股份。Two Sigma Advisers LP 在第四季度将其在 Aerovate Therapeutics 的持股增加了 38.5%。Two Sigma Advisers LP 现在拥有 153,600 股该公司的股票，价值 407,000 美元，此前在上个季度又购买了 42,700 股。Northern Trust Corp 在第四季度将其在 Aerovate Therapeutics 的持股增加了 6.3%。Northern Trust Corp 现在拥有 106,692 股该公司的股票，价值 283,000 美元，此前在上个季度又购买了 6,296 股。BNP Paribas Financial Markets 在第四季度以约 145,000 美元的价格购买了 Aerovate Therapeutics 的新头寸。Rhumbline Advisers 在第一季度将其在 Aerovate Therapeutics 的持股增加了 67.3%。Rhumbline Advisers 现在拥有 22,750 股该公司的股票，价值 57,000 美元，此前在此期间又购买了 9,154 股。最后，Squarepoint Ops LLC 在第四季度以约 52,000 美元的价格收购了 Aerovate Therapeutics 的新股份。</p>
<p>获取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
<h2>Aerovate Therapeutics 价格表现</h2>
<p>AVTE 周一开盘价为 7.77 美元。该公司的市值为 2.2521 亿美元，市盈率为-2.60，贝塔值为 0.95。Aerovate Therapeutics, Inc.的 1 年最低价为 56.35 美元，1 年最高价为 105.00 美元。该公司的 50 日移动平均价格为 8.43 美元，200 日移动平均价格为 35.97 美元。</p>
<h2>Aerovate Therapeutics 简介</h2>
<p>（免费报告）</p>
<p>Aerovate Therapeutics, Inc.是一家临床阶段的生物制药公司，开发能够改善美国罕见心肺疾病患者生活的药物。它专注于推进 AV-101，这是一种用于治疗肺动脉高压的干粉吸入剂，目前处于 2b/3 期临床试验中。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Aerovate Therapeutics</li>
<li>市值计算器：如何计算市值</li>
<li>联合太平洋：为美国工业复兴铺轨</li>
<li>百分比涨幅告诉投资者什么，以及为什么它们并未告诉全部故事</li>
<li>TransDigm 的优势：从备件到高额利润</li>
<li>REIT 股票 - 今天添加到您投资组合中的最佳 REIT 股票</li>
<li>Spire Global：微型卫星、大量买入评级和上涨空间</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>您现在应该投资 1,000 美元在 Aerovate Therapeutics 吗？</h2>
<p>在您考虑 Aerovate Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Aerovate Therapeutics 并不在名单上。</p>
<p>虽然 Aerovate Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

AVTE

<p>Nuveen LLC 已收购 Aerovate Therapeutics, Inc.（纳斯达克代码：AVTE）40,047 股，价值约 101,000 美元，占该公司约 0.14% 的股份。其他机构投资者也调整了他们的持股比例，其中 Two Sigma Advisers LP 增加了 38.5% 的持股。Aerovate Therapeutics 是一家临床阶段的生物制药公司，专注于开发稀有心肺疾病的治疗方案。该股票开盘价为 7.77 美元，市值为 2.2521 亿美元，市盈率为 -2.60</p>

<p>Nuveen LLC acquired a new position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 40,047 shares of the company's stock, valued at approximately $101,000. Nuveen LLC owned approximately 0.14% of Aerovate Therapeutics at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据 Nuveen LLC 最近向 SEC 提交的 13F 表格，该公司在第一季度收购了 Aerovate Therapeutics, Inc.（NASDAQ:AVTE - 免费报告）的新头寸。这家机构投资者收购了 40,047 股该公司的股票，价值约为 101,000 美元。截至最近报告期末，Nuveen LLC 持有 Aerovate Therapeutics 约 0.14% 的股份。</p>
</div><p>Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Two Sigma Advisers LP grew its holdings in Aerovate Therapeutics by 38.5% in the 4th quarter. Two Sigma Advisers LP now owns 153,600 shares of the company's stock worth $407,000 after buying an additional 42,700 shares in the last quarter. Northern Trust Corp grew its holdings in Aerovate Therapeutics by 6.3% in the 4th quarter. Northern Trust Corp now owns 106,692 shares of the company's stock worth $283,000 after buying an additional 6,296 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Aerovate Therapeutics in the 4th quarter worth approximately $145,000. Rhumbline Advisers lifted its position in Aerovate Therapeutics by 67.3% in the first quarter. Rhumbline Advisers now owns 22,750 shares of the company's stock worth $57,000 after purchasing an additional 9,154 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in Aerovate Therapeutics in the fourth quarter worth approximately $52,000.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金也增加或减少了在该公司的股份。Two Sigma Advisers LP 在第四季度将其在 Aerovate Therapeutics 的持股增加了 38.5%。Two Sigma Advisers LP 现在拥有 153,600 股该公司的股票，价值 407,000 美元，此前在上个季度又购买了 42,700 股。Northern Trust Corp 在第四季度将其在 Aerovate Therapeutics 的持股增加了 6.3%。Northern Trust Corp 现在拥有 106,692 股该公司的股票，价值 283,000 美元，此前在上个季度又购买了 6,296 股。BNP Paribas Financial Markets 在第四季度以约 145,000 美元的价格购买了 Aerovate Therapeutics 的新头寸。Rhumbline Advisers 在第一季度将其在 Aerovate Therapeutics 的持股增加了 67.3%。Rhumbline Advisers 现在拥有 22,750 股该公司的股票，价值 57,000 美元，此前在此期间又购买了 9,154 股。最后，Squarepoint Ops LLC 在第四季度以约 52,000 美元的价格收购了 Aerovate Therapeutics 的新股份。</p>
</div><p>Get <strong>Aerovate Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
</div><h2>Aerovate Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 价格表现</h2>
</div><p>AVTE opened at $7.77 on Monday. The company has a market capitalization of $225.21 million, a price-to-earnings ratio of -2.60 and a beta of 0.95. Aerovate Therapeutics, Inc. has a 1-year low of $56.35 and a 1-year high of $105.00. The business has a 50 day moving average price of $8.43 and a two-hundred day moving average price of $35.97.</p>
<div class="lb-trans"><p>AVTE 周一开盘价为 7.77 美元。该公司的市值为 2.2521 亿美元，市盈率为-2.60，贝塔值为 0.95。Aerovate Therapeutics, Inc.的 1 年最低价为 56.35 美元，1 年最高价为 105.00 美元。该公司的 50 日移动平均价格为 8.43 美元，200 日移动平均价格为 35.97 美元。</p>
</div><h2>Aerovate Therapeutics Profile</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p>
<div class="lb-trans"><p>Aerovate Therapeutics, Inc.是一家临床阶段的生物制药公司，开发能够改善美国罕见心肺疾病患者生活的药物。它专注于推进 AV-101，这是一种用于治疗肺动脉高压的干粉吸入剂，目前处于 2b/3 期临床试验中。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Aerovate Therapeutics</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Union Pacific: Laying the Tracks for America's Industrial Renewal</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>TransDigm’s Edge: From Spare Parts to Sky-High Profits</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Spire Global: Tiny Satellites, Big Buy Ratings and Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Aerovate Therapeutics</li>
<li>市值计算器：如何计算市值</li>
<li>联合太平洋：为美国工业复兴铺轨</li>
<li>百分比涨幅告诉投资者什么，以及为什么它们并未告诉全部故事</li>
<li>TransDigm 的优势：从备件到高额利润</li>
<li>REIT 股票 - 今天添加到您投资组合中的最佳 REIT 股票</li>
<li>Spire Global：微型卫星、大量买入评级和上涨空间</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AVTE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Aerovate Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Aerovate Therapeutics 吗？</h2>
</div><p>Before you consider Aerovate Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Aerovate Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Aerovate Therapeutics 并不在名单上。</p>
</div><p>While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aerovate Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Nuveen LLC 已收购了 Aerovate Therapeutics, Inc. $AVTE 的 40,047 股股票